Evotec SE (EVT.DE) Stock Analysis & Winston Score

Evotec is a German biotechnology company that helps other drug companies discover and develop new medicines. Instead of selling its own drugs to patients, it acts as a research partner — running experiments, testing compounds, and advancing drug candidates on behalf of pharmaceutical and biotech clients. The company operates what it calls an "integrated drug discovery" platform, serving major drugmakers like Bayer, Bristol-Myers Squibb, and Novo Nordisk. Evotec earns money through research service fees, milestone payments, and royalty agreements tied to drugs it helped develop. It operates primarily in Europe and the United States, with labs in Germany, the UK, France, and Italy, and employs roughly 4,000 people. Its main competitive advantage is its large network of scientific infrastructure and long-term partnerships, which are expensive for clients to replace. However, the company is currently unprofitable, and its thin gross margins mean it must carefully manage costs while trying to convert its drug pipeline partnerships into future royalty income.